Nawal Ouzren's guest appearances

Nawal Ouzren

Empowered Patient Podcast

Le Journal des Biotechs

Business Of Biotech

Alain Moussy

David Solomon

Daniel Cohen

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

Andrew Newberg

OwlTail

We often talk about biotechs taking "big swings." This week's guest is swinging for the fences with a lineup of gene therapies designed to address multiple forms of hearing loss, which affect multiple millions (if not, billions) of people worldwide. Adding to the challenge she's accepted, Sensorion CEO Nawal Ouzren is architecting an approach that seeks to restore hearing that's been lost due to genetic factors, treat sudden hearing disorders, and proactively prevent hearing loss due to common causes such as cisplatin induced ototoxicity or cochlear implantation. Listen in as Ouzren shares her holistic and aggressive plans with the Business of Biotech. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

We often talk about biotechs taking "big swings." This week's guest is swinging for the fences with a lineup of gene therapies designed to address multiple forms of hearing loss, which affect multiple millions (if not, billions) of people worldwide. Adding to the challenge she's accepted, Sensorion CEO Nawal Ouzren is architecting an approach that seeks to restore hearing that's been lost due to genetic factors, treat sudden hearing disorders, and proactively prevent hearing loss due to common causes such as cisplatin induced ototoxicity or cochlear implantation. Listen in as Ouzren shares her holistic and aggressive plans with the Business of Biotech. Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

Gene Tx For Hearing Loss with Sensorion's Nawal Ouzren

Le journal des biotechs du 16 juin 2022Le journal des biotechs : Nawal Ouzren (Sensorion), Frédéric Gomez (Pharmium Securities) Dans ce numéro du journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities, livre ses réflexions sur  les dossiers emblématiques de la cote biotech française et leur actualité récente : DBV Technologies et Valneva. Il en profite pour nous faire découvrir les qualités d'une biotech belge : Argenix. L'entretien est consacrée à Nawal Ouzren, directrice générale générale de Sensorion. Elle revient notamment sur l’approbation en France du lancement de l’essai clinique de « preuve de concept » de SENS-401 pour la préservation de l’audition résiduelle suite à une implantation cochléaire. Elle détaille l'avancée des programmes de thérapie génique en partenariat avec l'Institut Pasteur et évoque également le cours de Bourse de Sensorion.

Le journal des biotechs du 16 juin 2022 Le journal des biotechs : Nawal Ouzren (Sensorion), Frédéric Gomez (Pharmium Securities) Dans ce numéro du journal des biotechs, Frédéric Gomez, analyste chez Pharmium Securities, livre ses réflexions sur les dossiers emblématiques de la cote biotech française et leur actualité récente : DBV Technologies et Valneva. Il en profite pour nous faire découvrir les qualités d'une biotech belge : Argenix. L'entretien est consacrée à Nawal Ouzren, directrice générale générale de Sensorion. Elle revient notamment sur l’approbation en France du lancement de l’essai clinique de « preuve de concept » de SENS-401 pour la préservation de l’audition résiduelle suite à une implantation cochléaire. Elle détaille l'avancée des programmes de thérapie génique en partenariat avec l'Institut Pasteur et évoque également le cours de Bourse de Sensorion.

Le JDB : Nawal Ouzren (Sensorion), Frédéric Gomez (Pharmium Securities)

Nawal Ouzren, CEO, Sensorion talks about recent studies that have shown the dramatic impact of hearing loss on the elderly as well as children putting all at risk for social isolation. For kids hearing loss can hinder their social development, and for seniors it can increase their risk for dementia.  Nawal talks about the research at Sensorion and their lead clinical candidate SENS-401 which is showing great promise to prevent hearing loss particularly in children being treated for cancer. #hearingloss   #Sensorion   #SENS401 #InnerEarDisease @sensorionpharma Sensorion

Nawal Ouzren, CEO, Sensorion talks about recent studies that have shown the dramatic impact of hearing loss on the elderly as well as children putting all at risk for social isolation. For kids hearing loss can hinder their social development, and for seniors it can increase their risk for dementia.  Nawal talks about the research at Sensorion and their lead clinical candidate SENS-401 which is showing great promise to prevent hearing loss particularly in children being treated for cancer. #hearingloss   #Sensorion   #SENS401 #InnerEarDisease @sensorionpharma <a href="http://sensorion-pharma.com" rel="noopener nofollow" target="_blank">Sensorion</a>

True Impact of Hearing Loss and Approach Towards Treatment with Nawal Ouzren Sensorion